Prevalence and Management of Obesity in U.S. Adults With Type 1 Diabetes
Authors: Djordje Popovic, Dimitrios Patoulias, Nikolaos Papanas
Journal: Annals of Internal Medicine (2023)

LettersSeptember 2023Prevalence and Management of Obesity in U.S. Adults With Type 1 DiabetesDjordje Popovic, MD, PhD, Dimitrios Patoulias, MD, MSc, PhD, Nikolaos Papanas, MD, PhDDjordje Popovic, MD, PhDUniversity of Novi Sad, Novi Sad, Serbia, Dimitrios Patoulias, MD, MSc, PhDAristotle University of Thessaloniki, Thessaloniki, Greece, Nikolaos Papanas, MD, PhDDemocritus University of Thrace, Alexandroupolis, GreeceAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L23-0227 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR: Fang and colleagues (1) confirm the rising prevalence of overweight and obesity and the lack of adequate lifestyle counseling among patients with type 1 diabetes mellitus (T1DM). Unfortunately, the need for intensification of lifestyle interventions is mostly inevitable. Wide-range administration of certain antidiabetic drug classes with significant body weight–lowering effects proven in patients with type 2 diabetes could be of paramount importance.The most promising candidate drugs for this purpose are sodium–glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists. A previous network meta-analysis that included 58 randomized controlled trials assessed the efficacy and safety of ...References1. Fang M, Jeon Y, Echouffo-Tcheugui JB, et al. Prevalence and management of obesity in U.S. adults with type 1 diabetes. Ann Intern Med. 2023;176:427-429. [PMID: 36780652] doi:10.7326/M22-3078 LinkGoogle Scholar2. Avgerinos I, Manolopoulos A, Michailidis T, et al. Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: a systematic review and network meta-analysis. Diabetes Obes Metab. 2021;23:822-831. [PMID: 33300282] doi:10.1111/dom.14291 CrossrefMedlineGoogle Scholar3. Al-Ozairi E, Irshad M, Taghadom E, et al. Glucagon-like peptide-1 agonists combined with sodium-glucose cotransporter-2 inhibitors reduce weight in type 1 diabetes. Obesity (Silver Spring). 2023;31:716-723. [PMID: 36811241] doi:10.1002/oby.23677 CrossrefMedlineGoogle Scholar4. Musso G, Sircana A, Saba F, et al. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: a meta-analysis and meta-regression. PLoS Med. 2020;17:e1003461. [PMID: 33373368] doi:10.1371/journal.pmed.1003461 CrossrefMedlineGoogle Scholar5. Seufert J, Lanzinger S, Danne T, et al; DPV Initiative. Real-world data of 12-month adjunct sodium-glucose co-transporter-2 inhibitor treatment in type 1 diabetes from the German/Austrian DPV registry: Improved HbA1c without diabetic ketoacidosis [Letter]. Diabetes Obes Metab. 2022;24:742-746. [PMID: 34897941] doi:10.1111/dom.14620 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Djordje Popovic, MD, PhD; Dimitrios Patoulias, MD, MSc, PhD; Nikolaos Papanas, MD, PhDAffiliations: University of Novi Sad, Novi Sad, SerbiaAristotle University of Thessaloniki, Thessaloniki, GreeceDemocritus University of Thrace, Alexandroupolis, GreeceDisclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L23-0227. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoPrevalence and Management of Obesity in U.S. Adults With Type 1 Diabetes Michael Fang , Yein Jeon , Justin B. Echouffo-Tcheugui , Elizabeth Selvin Prevalence and Management of Obesity in U.S. Adults With Type 1 Diabetes Michael Fang , Justin B. Echouffo-Tcheugui , Elizabeth Selvin Metrics Current IssueSeptember 2023Volume 176, Issue 9KeywordsDietExerciseHealth surveysInsulinObesityOverweightPrevention, policy, and public healthType 1 diabetesType 2 diabetesWeight loss ePublished: 19 September 2023 Issue Published: September 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...